| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
SIMAGCHEM CORP |
| Tel: |
+86-5922680277 +86-13806087780 |
| Email: |
sale@simagchem.com |
- Edatrexate
-
- $3120.00
-
2026-05-21
- CAS:80576-83-6
- Purity:
- Supply Ability: 10g
|
| | Edatrexate Basic information |
| Product Name: | Edatrexate | | Synonyms: | (S)-2-[4-[1-[(2,4-Diaminopteridine-6-yl)methyl]propyl]benzoylamino]pentanedioic acid;10-Ethyl-10-deazaaminopterin;10-Ethyl-10-deazaaminopterine;EDX;N-[4-[1-[(2,4-Diaminopteridin-6-yl)methyl]propyl]benzoyl]-L-glutamic acid;CGP 30694;NSC 626715;FSIRXIHZBIXHKT-MHTVFEQDSA-N | | CAS: | 80576-83-6 | | MF: | C22H25N7O5 | | MW: | 467.48 | | EINECS: | | | Product Categories: | | | Mol File: | 80576-83-6.mol |  |
| | Edatrexate Chemical Properties |
| density | 1.441±0.06 g/cm3(Predicted) | | pka | 3.56±0.10(Predicted) |
| | Edatrexate Usage And Synthesis |
| Uses | Antineoplastic. | | Definition | ChEBI: Edatrexate is a glutamic acid derivative. | | in vivo | Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX[1].
| Animal Model: | Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)[2] | | Dosage: | 0.14 g/kg and 0.21 g/kg | | Administration: | Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment | | Result: | Increased survival of tumor-bearing mice.
Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue. |
|
| | Edatrexate Preparation Products And Raw materials |
|